Hepatitis 13 and liver transplantation

Clinical Infectious Diseases

Volumn 41, Issue 10, 2005, Pages 1461-1466

  Tung, Brace Y ^a   Kowdley, Kris V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; CREATININE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CHRONIC HEPATITIS; CYTOPENIA; DISEASE EXACERBATION; DRUG COST; GRAFT SURVIVAL; HEPATITIS B; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; INFECTION RISK; LIVER FAILURE; LIVER GRAFT; LIVER TRANSPLANTATION; MONOTHERAPY; NEPHROTOXICITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; REINFECTION; VIREMIA; VIRUS LOAD; VIRUS MUTATION; RECURRENT DISEASE; REVIEW; RISK FACTOR; VIROLOGY;

ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; RECURRENCE; RISK FACTORS;

EID: 27644450938     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/497129     Document Type: Article

References (29)

1. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:1842-7.
2. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10:968-74.
3. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323:295-301.
4. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660-7.
5. Lin S-H, Sheen I-S, Chien R-N, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-5.
6. Ikeda K, Kobayashi M, Saitoh S, et al. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study. J Gastroenterol Hepatol 2005; 20:95-102.
7. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31:207-10.
8. Fontana RJ, Keeffe EB, Carey W, et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8:433-9.
9. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-31.
10. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-32.
11. Schiff ER, Lai C-L, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003; 38:1419-27.
12. Hadziyannis S, Tassopoulos N, Chang TT, et al. Adefovir dipivoxil demonstrates sustained efficacy in HBeAg-negative chronic hepatitis B patients [abstract 322]. Gastroenterology 2005; 128:A-693.
13. Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg(+) chronic hepatitis B: results of phase III study ETV-022 in nucleoside-naive patients [abstract 70]. Hepatology 2004; 40:193A.
14. Kuo, A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004; 2:266-72.
15. Brind A, Jiang J, Samuel D, et al. Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection. J Hepatol 1997; 26:228-35.
16. Schilling R, Ijaz S, Davidoff M, et al. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77:8882-92.
17. Protzer-Knolle U, Naumann U, Bartenschlager R, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 1998; 27:254-63.
18. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27:213-22.
19. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 2003; 38:86-95.
20. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348:1212-5.
21. Perrillo RP, Wright T, Rakela J, et al. A multi-center United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33:424-32.
22. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34:903-10.
23. Han SH, Martin P, Edelstein M, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003; 9:182-7.
24. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38:811-7.
25. Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001; 34:888-94.
26. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31:496-501.
27. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35:176-81.
28. Bienzle U, Gunther M, Neuhaus R, et al. Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology 2003; 38:811-9.
29. Perrillo RP, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:1581-6.